Fujisawa Pharmaceutical Company, Ltd.

Suntory Holdings Limited

Masamichi Satoh

Nobuya Matsuoka

Hideo Saji

Keiko Shimamoto

Takayuki Nakagawa

Yuji Kuge

Masashi Ueda

The present invention provides a radiolabeled ligand which is highly selective and potent for glutamate transporters and is usable in specifically detecting the glutamate transporter. Specifically, the present invention provides a 3-[3-(benzoylamido)benzyloxy]aspartic acid having a radioactive substituent on the benzoyl group which is represented by the following formula (1), or an ester or salt thereof: wherein X represents a substituent containing a radioactive atom(s) which is selected from a straight or branched lower aliphatic alkyl group, a hydroxyl group, a straight or branched lower aliphatic alkoxy group, an amino group, a straight or branched lower aliphatic acylamido group, a halogen atom and a straight or branched lower aliphatic haloalkyl group; and Rand Reach represents a hydrogen atom, a straight or branched lower aliphatic alkyl group or an acetoxymethyl group.

Radiolabeled 3-[3-(benzoyl-amido)benzyloxy]aspartic acid derivative and method of producing the same

The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.

Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a soniatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.

Growing community of inventors

Kyoto, Japan

Masamichi Satoh